SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S. Advani(Cleveland Clinic), Harry P. Erba(Michigan Center for Translational Pathology), Rupali Bhave(Atrium Health Wake Forest Baptist), Kristen M. O’Dwyer(University of Rochester Medical Center), Brent L. Wood(University of Southern California), Elad Sharon(National Cancer Institute), Anna Moseley(Fred Hutch Cancer Center), Megan Othus(Cancer Research And Biostatistics), Rebecca B. Klisovic(Goethe University Frankfurt), Ibrahim Aldoss(City of Hope), Min Fang(Zhejiang International Studies University), Maria R. Baer(University of Maryland, Baltimore), Cheryl L. Willman(Mayo Clinic), Richard C. Harvey(University of New Mexico), Richard M. Stone(Dana-Farber Cancer Institute), Mark R. Litzow(Mayo Clinic in Arizona), Wendy Stock(University of Chicago), Jae H. Park(Memorial Sloan Kettering Cancer Center), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist)
UNM’s Digital Repository (University of New Mexico)
May 10, 2022
Cited by 85
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k